The latest financial data from biotechnology company Tscan Therapeutics, Inc. shows that its current cash and cash equivalents are sufficient to support the company's daily operations and R&D investment through the second half of 2027.

The latest financial data from biotechnology company Tscan Therapeutics, Inc. shows that its current cash and cash equivalents are sufficient to support the company's daily operations and R&D investment through the second half of 2027.

老虎证券2026/03/04 12:34

Show original

This capital reserve provides the company with stable financial support for advancing the development of tumor-targeted therapies, demonstrating the enterprise's robust approach to capital management.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

The latest financial data from biotechnology company Tscan Therapeutics, Inc. shows that its current cash and cash equivalents are sufficient to support the company's daily operations and R&D investment through the second half of 2027.

You may also like

Trending news

Crypto prices